Professor Daniel Markl
Strathclyde Institute of Pharmacy and Biomedical Sciences
Personal statement
Daniel Markl鈥檚 research focuses on developing predictive systems, in-silico design methods and self-driving labs for drug product development and manufacturing that accelerate the pace at which new medicines are developed and delivered. He obtained a BSc (2010) and MSc (2012) in telematics with a focus on neural networks and a PhD (2015) in chemical engineering from Graz University of Technology. Daniel secured an Erasmus Mundus in 2010, which allowed him to study modelling and control system design for one year during his MSc at Lund University. During his PhD he was employed by the Research Center Pharmaceutical Engineering (RCPE) GmbH, where he was in the group Process and Manufacturing Science and involved in several projects at the interface of pharmaceutical engineering, materials science and process modelling. He continued as Senior Scientist and Scientific Project Leader at RCPE after completing his PhD. In 2016 he joined Professor Zeitler鈥檚 group (Terahertz Applications Group) as a postdoctoral research associate at the University of Cambridge. Daniel worked for two years in the Terahertz Applications Group before becoming a Chancellor鈥檚 Fellow and Lecturer/Assistant Professor at the 糖心视频 in the Strathclyde Institute of Pharmacy and Biomedical Sciences (SIPBS).
Daniel is Associate Director at CMAC (), Training Director of the EPSRC Centre of Doctoral Training in Cyberphysical Systems for Medicines Development and Manufacturing and leads the MHRA-funded Centre of Excellence in Regulatory Science and Innovation (CERSI) for the digital transformation of medicines development and manufacturing.聽
Prize And Awards
- Recipient
- 2020
- Recipient
- 2020
- Recipient
- 2019
- Recipient
- 2016
- Recipient
- 2010
Publications
- , , Hou Peter, , , , , Portela Victor, Boulay Quentin, Thiolliere Roland, Stark Ashley, Schwartz Jean-Jacques, Guerin Jerome, Maloney Andrew GP, Moldovan Alexandru A, Reynolds Gavin, Mantanus J茅r么me, Clark Catriona, Chapman Paul, ,
- Nature Communications (2026)
- , , ,
- CMAC Open Days 2026 (2026)
- , Abrahms茅n-Alami Susanna, Clark Catriona, D枚rr Frederik, , Ketolainen Jarkko, Lindow Morten, Mantanus J茅r么me, Rantanen Jukka, Reynolds Gavin, Robertson Amy,
- European Journal of Pharmaceutical Sciences Vol 220 (2026)
- , , , Naftaly Mira
- 2025 50th International Conference on Infrared, Millimeter, and Terahertz Waves (IRMMW-THz) 2025 50th International Conference on Infrared, Millimeter, and Terahertz Waves (IRMMW-THz) 2025 50th International Conference on Infrared, Millimeter, and Terahertz Waves (IRMMW-THz), pp. 1-2 (2026)
- Gorecki Jon, Murphy Keir N, , Burnett Andrew D, Naftaly Mira
- 2025 50th International Conference on Infrared, Millimeter, and Terahertz Waves (IRMMW-THz) (2026)
- , Mann James, Abbott Alexander, Winge Fredrik, Davis Adrian, Hens Bart, ,
- International Journal of Pharmaceutics Vol 684 (2025)
Research Interests
Our laboratory conducts multidisciplinary research at the intersection of materials, processes, products, and performance, with the goal of transforming how medicines are designed, developed, and manufactured. We seek to establish a fundamental, predictive understanding of how material properties and processing conditions jointly determine product structure, quality, and performance.
Central to our approach is the coupling of self-driving laboratories, advanced measurement techniques, and digital process and product design. By integrating automation, high-throughput experimentation, real-time analytics, and data-driven modeling, we aim to dramatically accelerate development timelines while improving robustness, efficiency, and knowledge generation across the pharmaceutical lifecycle.
Our research includes the development of predictive systems, in-silico design methods, and autonomous experimental platforms for drug product development and manufacturing. These tools enable rapid exploration of complex formulation and process spaces, support rational decision-making, and reduce reliance on trial-and-error experimentation. Ultimately, our work lays the foundation for adaptive, intelligent manufacturing systems that deliver higher-quality medicines more efficiently and reliably.
Professional Activities
- Speaker
- 2025
- Speaker
- 2025
- Speaker
- 2025
- Speaker
- 2024
- Speaker
- 2024
- Speaker
- 2024
Projects
- Markl, Daniel (Principal Investigator) Florence, Alastair (Co-investigator)
- 01-Jan-2025 - 30-Jan-2026
- Markl, Daniel (Principal Investigator) Florence, Alastair (Co-investigator) Johnston, Blair (Co-investigator)
- 01-Jan-2025 - 31-Jan-2026
- Nordon, Alison (Principal Investigator) Littlejohn, David (Co-investigator) Markl, Daniel (Co-investigator)
- 01-Jan-2025 - 30-Jan-2025
- Fitzpatrick, Stephen (Principal Investigator) Florence, Alastair (Principal Investigator) Florence, Alastair (Co-investigator) Johnston, Blair (Co-investigator) Markl, Daniel (Co-investigator)
- 01-Jan-2025 - 30-Jan-2025
- Markl, Daniel (Principal Investigator) Macdonald, Janine (Co-investigator)
- 25-Jan-2024 - 19-Jan-2024
- Florence, Alastair (Principal Investigator) Brown, Cameron (Co-investigator) Cardona Amengual, Javier (Co-investigator) Johnston, Blair (Co-investigator) Markl, Daniel (Co-investigator) Nordon, Alison (Co-investigator) Robertson, John (Co-investigator) Sefcik, Jan (Co-investigator)
- 01-Jan-2024 - 30-Jan-2031
Contact
Professor
Daniel
Markl
Strathclyde Institute of Pharmacy and Biomedical Sciences
Email: daniel.markl@strath.ac.uk
Tel: 444 7115